Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2019

View Archived Issues

CTC clusters affect methylation and metastasis

Iron transporter to the (retinal) rescue

Targeting transferrin receptor protein 2 knockout alleviates anemia in a model of beta-thalassemia

INTS1 gene variants tied to intellectual disability with eye defects and craniofacial anomalies

Comprehensive characterization of the GPCR nature of FZD5

In vitro studies interpret in vivo PK profile of S-012-1332

Phase II data for PF-04457845 as potential treatment of cannabis withdrawal and dependence

Osterix as a novel target for the control of bone metastasis in breast cancers

Phase I/II data presented from the PhagoBurn study of PP-1131

Sound Pharmaceuticals enrolls first patient in STOP Ototoxicity phase II study of SPI-1005

Bionor acquires HIV vaccine candidate Vacc-CRX from Immunor

Nash Pharmaceuticals reports preclinical activity and new compounds for kidney disease

New NATALEE trial tests ribociclib and endocrine therapy for HR+/HER2- early breast cancer

FDA approves Cabometyx for previously treated HCC

European approval for Opdivo with Yervoy for first-line intermediate- and poor-risk advanced RCC

City of Hope National Medical Center discovers poly(ADP-ribose) glycohydrolase inhibitors

Accro Bioscience patents necrosis inhibitors

Heat Biologics begins dosing in new phase II cohort of HS-110 with pembrolizumab for advanced NSCLC

Mining secondary metabolome yields anti-infective leads

New phase I trial to attack Alzheimer's by targeting inflammation in the brain's blood vessels

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.